Anti-Parkinson's disease drugs and pharmacogenetic considerations

Bibliography

• CPIC. Clinical Pharmacogenetics Implementation Consortium. 2013. Available from: http://www.pharmgkb.org/page/cpic [Last accessed 31 January 2013]
   Google Scholar
• Fox SH, Katzenschlager R, Lim SY, et al. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011;26(Suppl 3):S2-41
   PubMed Web of Science ®Google Scholar
• Nation RL, Triggs EJ, Vine J. Metabolism and urinary excretion of benzhexol in humans. Xenobiotica 1978;8(3):165-9
   PubMed Web of Science ®Google Scholar
• Capka V, Xu Y, Chen YH. Stereoselective determination of trihexyphenidyl in human serum by LC-ESI-MS. J Pharm Biomed Anal 1999;21(3):507-17
   PubMed Web of Science ®Google Scholar
• He H, McKay G, Midha KK. Phase I and II metabolites of benztropine in rat urine and bile. Xenobiotica 1995;25(8):857-72
   PubMed Web of Science ®Google Scholar
• Burke RE, Fahn S. Pharmacokinetics of trihexyphenidyl after short-term and long-term administration to dystonic patients. Ann Neurol 1985;18(1):35-40
   PubMed Web of Science ®Google Scholar
• Cheung WK, Stravinski SS, Engel SI, et al. Pharmacokinetic evaluation of a sustained-release formulation of trihexyphenidyl in healthy volunteers. J Pharm Sci 1988;77(9):748-50
   PubMed Web of Science ®Google Scholar
• DrugBank. Open Data Drug & Drug Target Database. 2013. Available from: http://www.drugbank.ca/ [Last accesed 31 January 2013]
   Google Scholar
• PharmGkb. The Pharmacogenomics Knowledgebase. 2013. Available from: http://www.pharmgkb.org [Last accesed 31 January 2013]
   Google Scholar
• Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 2013;9(2):106-18
   PubMed Web of Science ®Google Scholar
• Pomara N, Willoughby LM, Wesnes K, et al. Increased anticholinergic challenge-induced memory impairment associated with the APOE-epsilon4 allele in the elderly: a controlled pilot study. Neuropsychopharmacology 2004;29(2):403-9
   PubMed Web of Science ®Google Scholar
• Hollmann M, Brode E, Greger G, et al. Biperiden effects and plasma levels in volunteers. Eur J Clin Pharmacol 1984;27(5):619-21
   PubMed Web of Science ®Google Scholar
• Grimaldi R, Perucca E, Ruberto G, et al. Pharmacokinetic and pharmacodynamic studies following the intravenous and oral administration of the antiparkinsonian drug biperiden to normal subjects. Eur J Clin Pharmacol 1986;29(6):735-7
   PubMed Web of Science ®Google Scholar
• Othman AA, Syed SA, Newman AH, et al. Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. J Pharmacol Exp Ther 2007;320(1):344-53
   PubMed Web of Science ®Google Scholar
• Zanger UM, Turpeinen M, Klein K, et al. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 2008;392(6):1093-108
   PubMed Web of Science ®Google Scholar
• P450. Drug Interaction Table. 2013. Available from: http://medicine.iupui.edu/clinpharm/ddis/table.aspx [Last accessed 31 January 2013]
   Google Scholar
• Benitez J, Ladero JM, Jimenez-Jimenez FJ, et al. Oxidative polymorphism of debrisoquine in Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53(4):289-92
   PubMed Web of Science ®Google Scholar
• Agundez JA, Del Barrio J, Padro T, et al. Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the spanish society of clinical pharmacology. Front Pharmacol 2012;3:2
   Google Scholar
• U.S._FDA. Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labels. 2013. Available from: http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm [Last accessed 31 January 2013]
   Google Scholar
• CYP2C19. Allele nomenclature. 2013. Available from: http://www.cypalleles.ki.se/cyp2c19.htm [Last accessed 31 January 2013]
   Google Scholar
• CYP2D6. Allele nomenclature. 2013. Available from: http://www.cypalleles.ki.se/cyp2d6.htm [Last accessed 31 January 2013]
   Google Scholar
• 1000_Genomes. A Deep Catalog of Human Genetic Variation. 2013. Available from: http://browser.1000genomes.org/index.html [Last accessed 31 January 2013]
   Google Scholar
• Koppel C, Tenczer J. A revision of the metabolic disposition of amantadine. Biomed Mass Spectrom 1985;12(9):499-501
   PubMedGoogle Scholar
• Bras AP, Hoff HR, Aoki FY, et al. Amantadine acetylation may be effected by acetyltransferases other than NAT1 or NAT2. Can J Physiol Pharmacol 1998;76(7-8):701-6
   PubMed Web of Science ®Google Scholar
• Bras AP, Janne J, Porter CW, et al. Spermidine/spermine n(1)-acetyltransferase catalyzes amantadine acetylation. Drug Metab Dispos 2001;29(5):676-80
   PubMed Web of Science ®Google Scholar
• Bialecka M, Kurzawski M, Klodowska-Duda G, et al. The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications. Pharmacogenet Genomics 2008;18(9):815-21
   PubMed Web of Science ®Google Scholar
• Yeh KC, August TF, Bush DF, et al. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology 1989;39(11 Suppl 2):25-38
   PubMed Web of Science ®Google Scholar
• Bartholini G, Burkard WP, Pletscher A. Increase of cerebral catecholamines caused by 3,4-dihydroxyphenylalanine after inhibition of peripheral decarboxylase. Nature 1967;215(5103):852-3
   PubMed Web of Science ®Google Scholar
• Marsden CD, Parkes JD, Rees JE. A year's comparison of treatment of patients with parkinson's disease with levodopa combined with carbidopa versus treatment with levodopa alone. Lancet 1973;2(7844):1459-62
   PubMed Web of Science ®Google Scholar
• Markham C, Diamond SG, Treciokas LJ. Carbidopa in Parkinson disease and in nausea and vomiting of levodopa. Arch Neurol 1974;31(2):128-33
   PubMed Web of Science ®Google Scholar
• Vickers S, Stuart EK, Bianchine JR, et al. Metabolism of carbidopa (1-(-)-alpha-hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate), an aromatic amino acid decarboxylase inhibitor, in the rat, rhesus monkey, and man. Drug Metab Dispos 1974;2(1):9-22
   PubMed Web of Science ®Google Scholar
• Sagar KA, Smyth MR. Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection. Analyst 2000;125(3):439-45
   PubMed Web of Science ®Google Scholar
• Cesar IC, Byrro RM, Santana ESCFF, et al. Development and validation of a high-performance liquid chromatography-electrospray ionization-MS/MS method for the simultaneous quantitation of levodopa and carbidopa in human plasma. J Mass spectrom 2011;46(9):943-8
   PubMed Web of Science ®Google Scholar
• Durso R, Evans JE, Josephs E, et al. Variable absorption of carbidopa affects both peripheral and central levodopa metabolism. J Clin Pharmacol 2000;40(8):854-60
   PubMed Web of Science ®Google Scholar
• Brod LS, Aldred JL, Nutt JG. Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease. Mov Disord 2012;27(6):750-3
   PubMed Web of Science ®Google Scholar
• Schwartz DE, Jordan JC, Ziegler WH. Pharmacokinetics of the decarboxylase inhibitor benserazide in man; its tissue distribution in the rat. Eur J Clin Pharmacol 1974;7(1):39-45
   PubMed Web of Science ®Google Scholar
• Jorga KM, Larsen JP, Beiske A, et al. The effect of tolcapone on the pharmacokinetics of benserazide. Eur J Neurol 1999;6(2):211-19
   PubMed Web of Science ®Google Scholar
• Breitling LP, Muller H, Illig T, et al. Dopamine-related genes and spontaneous smoking cessation in ever-heavy smokers. Pharmacogenomics 2011;12(8):1099-106
   PubMed Web of Science ®Google Scholar
• Maurer G, Schreier E, Delaborde S, et al. Fate and disposition of bromocriptine in animals and man. II: absorption, elimination and metabolism. Eur J Drug Metab Pharmacokinet 1983;8(1):51-62
   PubMed Web of Science ®Google Scholar
• Isin EM, Guengerich FP. Kinetics and thermodynamics of ligand binding by cytochrome P450 3A4. J Biol Chem 2006;281(14):9127-36
   PubMed Web of Science ®Google Scholar
• Matsubayashi K, Matsumoto H, Fukui Y. Contribution of cytochrome P450 3A pathway to bromocriptine metabolism and effects of ferrous iron and hypoxia-re-oxygenation on its elimination in the perfused rat liver. J Pharm Pharmacol 1997;49(5):551-7
   PubMed Web of Science ®Google Scholar
• Humpel M, Sostarek D, Gieschen H, et al. Studies on the biotransformation of lonazolac, bromerguride, lisuride and terguride in laboratory animals and their hepatocytes. Xenobiotica 1989;19(4):361-77
   PubMed Web of Science ®Google Scholar
• Bychkov E, Ahmed MR, Dalby KN, et al. Dopamine depletion and subsequent treatment with L-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum. J Neurochem 2007;102(3):699-711
   PubMed Web of Science ®Google Scholar
• Wynalda MA, Wienkers LC. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab Dispos 1997;25(10):1211-14
   PubMed Web of Science ®Google Scholar
• Kvernmo T, Hartter S, Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 2006;28(8):1065-78
   PubMed Web of Science ®Google Scholar
• Andreotti AC, Pianezzola E, Persiani S, et al. Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in healthy male volunteers. J Clin Endocrinol Metab 1995;80(3):841-5
   PubMed Web of Science ®Google Scholar
• Nakatsuka A, Nagai M, Yabe H, et al. Effect of clarithromycin on the pharmacokinetics of cabergoline in healthy controls and in patients with Parkinson's disease. J Pharmacol Sci 2006;100(1):59-64
   PubMed Web of Science ®Google Scholar
• Garcia-Martin E, Martinez C, Pizarro RM, et al. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin Pharmacol Ther 2002;71(3):196-204
   PubMed Web of Science ®Google Scholar
• CYP3A4. Allele nomenclature. 2013. Available from: http://www.cypalleles.ki.se/cyp3a4.htm [Last accessed 31 January 2013]
   Google Scholar
• Klein K, Zanger UM. Pharmacogenomics of cytochrome P450 3A4 (CYP3A4): recent progress towards the “missing heritability” problem. Front Genet 2013;4:12
   PubMedGoogle Scholar
• Nelson MV, Berchou RC, Kareti D, et al. Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine. Clin Pharmacol Ther 1990;47(6):694-7
   PubMed Web of Science ®Google Scholar
• Lu WJ, Huang K, Lai ML, et al. Erythromycin alters the pharmacokinetics of bromocriptine by inhibition of organic anion transporting polypeptide C-mediated uptake. Clin Pharmacol Ther 2006;80(4):421-2
   PubMed Web of Science ®Google Scholar
• Christensen J, Dupont E, ØStergaard K. Cabergoline plasma concentration is increased during concomitant treatment with itraconazole. Mov Disord 2002;17(6):1360-2
   PubMed Web of Science ®Google Scholar
• Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet 2000;39(4):243-54
   PubMed Web of Science ®Google Scholar
• CYP1A2. Allele nomenclature. 2013. Available from: http://www.cypalleles.ki.se/cyp1a2.htm [Last accessed 31 January 2013]
   Google Scholar
• Zhou SF, Wang B, Yang LP, et al. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev 2010;42(2):268-354
   PubMed Web of Science ®Google Scholar
• Wright CE, Sisson TL, Ichhpurani AK, et al. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol 1997;37(6):520-5
   PubMed Web of Science ®Google Scholar
• Cawello W, Braun M, Boekens H. Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery. Drug Metab Dispos 2009;37(10):2055-60
   PubMed Web of Science ®Google Scholar
• Cawello W, Ahrweiler S, Sulowicz W, et al. Single dose pharmacokinetics of the transdermal rotigotine patch in patients with impaired renal function. Br J Clin Pharmacol 2012;73(1):46-54
   PubMed Web of Science ®Google Scholar
• LeWitt PA. Subcutaneously administered apomorphine: pharmacokinetics and metabolism. Neurology 2004;62(6 Suppl 4):S8-11
   PubMed Web of Science ®Google Scholar
• Neef C, van Laar T. Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease. Clin Pharmacokinet 1999;37(3):257-71
   PubMed Web of Science ®Google Scholar
• Kalinderi K, Fidani L, Katsarou Z, et al. Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease. Int J Clin Pract 2011;65(12):1289-94
   PubMed Web of Science ®Google Scholar
• Rieck M, Schumacher-Schuh AF, Altmann V, et al. DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients. Pharmacogenomics 2012;13(15):1701-10
   PubMed Web of Science ®Google Scholar
• Strong JA, Dalvi A, Revilla FJ, et al. Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease. Mov Disord 2006;21(5):654-9
   PubMed Web of Science ®Google Scholar
• Arbouw ME, Movig KL, Egberts TC, et al. Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease. Eur J Clin Pharmacol 2009;65(12):1245-51
   PubMed Web of Science ®Google Scholar
• Liu YZ, Tang BS, Yan XX, et al. Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients. Eur J Clin Pharmacol 2009;65(7):679-83
   PubMed Web of Science ®Google Scholar
• McGuire V, Van Den Eeden SK, Tanner CM, et al. Association of DRD2 and DRD3 polymorphisms with Parkinson's disease in a multiethnic consortium. J Neurol Sci 2011;307(1-2):22-9
   PubMed Web of Science ®Google Scholar
• Garcia-Martin E, Martinez C, Alonso-Navarro H, et al. Dopamine receptor D3 (DRD3) genotype and allelic variants and risk for essential tremor. Mov Disord 2009;24(13):1910-15
   PubMed Web of Science ®Google Scholar
• Jimenez-Jimenez FJ, Alonso-Navarro H, Martinez C, et al. Dopamine receptor D3 (DRD3) gene rs6280 variant and risk for restless legs syndrome. Sleep Med 2013; Epub ahead of print
   Google Scholar
• Kamada T, Chow T, Hiroi T, et al. Metabolism of selegiline hydrochloride, a selective monoamine b-type inhibitor, in human liver microsomes. Drug Metab Pharmacokinet 2002;17(3):199-206
   PubMedGoogle Scholar
• Benetton SA, Fang C, Yang YO, et al. P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine. Drug Metab Pharmacokinet 2007;22(2):78-87
   PubMed Web of Science ®Google Scholar
• Slawson MH, Taccogno JL, Foltz RL, et al. Quantitative analysis of selegiline and three metabolites (N-desmethylselegiline, methamphetamine, and amphetamine) in human plasma by high-performance liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. J Anal Toxicol 2002;26(7):430-7
   PubMed Web of Science ®Google Scholar
• Mahmood I. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Clin Pharmacokinet 1997;33(2):91-102
   PubMed Web of Science ®Google Scholar
• CYP2B6. Allele nomenclature. 2013. Available from: http://www.cypalleles.ki.se/cyp2b6.htm [Last accessed 31 January 2013]
   Google Scholar
• Zanger UM, Klein K. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front Genet 2013;4:24
   PubMedGoogle Scholar
• Restrepo JG, Martinez C, Garcia-Agundez A, et al. Cytochrome P450 CYP2B6 genotypes and haplotypes in a Colombian population: identification of novel variant CYP2B6 alleles. Pharmacogenet Genomics 2011;21(12):773-8
   PubMed Web of Science ®Google Scholar
• Laine K, Anttila M, Nyman L, et al. CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline. Eur J Clin Pharmacol 2001;57(2):137-42
   PubMed Web of Science ®Google Scholar
• Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006;79(1):103-13
   PubMed Web of Science ®Google Scholar
• Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361(13):1268-78
   PubMed Web of Science ®Google Scholar
• Guay DR. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. Am J Geriatr Pharmacother 2006;4(4):330-46
   PubMedGoogle Scholar
• Bialecka M, Drozdzik M, Klodowska-Duda G, et al. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease. Acta Neurol Scand 2004;110(4):260-6
   PubMed Web of Science ®Google Scholar
• Heikkinen H, Saraheimo M, Antila S, et al. Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. Eur J Clin Pharmacol 2001;56(11):821-6
   PubMed Web of Science ®Google Scholar
• Keranen T, Gordin A, Karlsson M, et al. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol 1994;46(2):151-7
   PubMed Web of Science ®Google Scholar
• Gordin A, Kaakkola S, Teravainen H. Clinical advantages of COMT inhibition with entacapone - a review. J Neural Transm 2004;111(10-11):1343-63
   PubMed Web of Science ®Google Scholar
• Lautala P, Ethell BT, Taskinen J, et al. The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos 2000;28(11):1385-9
   PubMed Web of Science ®Google Scholar
• Borges N. Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy. Expert Opin Drug Saf 2005;4(1):69-73
   PubMedGoogle Scholar
• Andrade RJ, Agundez JA, Lucena MI, et al. Pharmacogenomics in drug induced liver injury. Curr Drug Metab 2009;10(9):956-70
   PubMed Web of Science ®Google Scholar
• Stocchi F, De Pandis MF. Utility of tolcapone in fluctuating Parkinson's disease. Clin Interv Aging 2006;1(4):317-25
   PubMed Web of Science ®Google Scholar
• Jorga KM, Kroodsma JM, Fotteler B, et al. Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites. Clin Pharmacol Ther 1998;63(6):646-54
   PubMed Web of Science ®Google Scholar
• Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005;4(6):489-99
   PubMed Web of Science ®Google Scholar
• Lotta T, Vidgren J, Tilgmann C, et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995;34(13):4202-10
   PubMed Web of Science ®Google Scholar
• Corvol JC, Bonnet C, Charbonnier-Beaupel F, et al. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial. Ann Neurol 2011;69(1):111-18
   PubMed Web of Science ®Google Scholar
• Chong DJ, Suchowersky O, Szumlanski C, et al. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease. Clin Neuropharmacol 2000;23(3):143-8
   PubMed Web of Science ®Google Scholar
• Garcia-Martin E, Martinez C, Ladero JM, et al. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther 2006;10(1):29-40
   PubMed Web of Science ®Google Scholar
• Garcia-Martin E. Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms. Curr Drug Metab 2008;9(6):487-97
   PubMed Web of Science ®Google Scholar
• Ledesma MC, Agundez JA. Identification of subtypes of CYP2D gene rearrangements among carriers of CYP2D6 gene deletion and duplication. Clin Chem 2005;51(6):939-43
   PubMed Web of Science ®Google Scholar
• Agundez JA, Golka K, Martinez C, et al. Unraveling ambiguous NAT2 genotyping data. Clin Chem 2008;54(8):1390-4
   PubMed Web of Science ®Google Scholar
• Ruiz JD, Martinez C, Anderson K, et al. The differential effect of NAT2 variant alleles permits refinement in phenotype inference and identifies a very slow acetylation genotype. PloS One 2012;7(9):e44629
   PubMed Web of Science ®Google Scholar
• Houle D, Govindaraju DR, Omholt S. Phenomics: the next challenge. Nat Rev Genet 2010;11(12):855-66
   PubMed Web of Science ®Google Scholar
• Agundez JA, Garcia-Martin E, Martinez C. Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin Drug Metab Toxicol 2009;5(6):607-20
   PubMed Web of Science ®Google Scholar